Skip to main content

Table 4 The relationship between clinico-pathological characteristics of patients with ER positive primary operable invasive ductal breast cancer and cancer- specific survival

From: The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer

      Univariate survival analysis     Multivariate survival analysis
       Cancer-specific survival      Cancer-specific survival
     Hazard ratio P-value    Hazard ratio P-value
      (95% CI)       (95% CI)  
Age (<50/>50 years) 1.82 (0.77-4.33) 0.173   
Size (≤20/21-50/>50 mm) 2.04 (1.20-3.49) 0.009   0.116
Grade (I/II/III) 1.71 (1.09-2.68) 0.019   0.342
Involved lymph node (0/1-3/>3) 2.26 (1.54-3.32) <0.001 2.11 (1.40-3.20) <0.001
Progesterone -receptor status (PR-/PR+) 0.72 (0.38-1.37) 0.316   
HER-2 status (HER-2 -/HER-2+) 2.17 (0.96-4.88) 0.062   0.109
Ki-67 status (Low Ki-67/High Ki-67) 3.71 (1.98-6.96) <0.001 3.62 (1.88-7.00) <0.001
LVI (Absent/Present) 2.98 (1.62-5.47) <0.001 2.36 (1.22-4.58) 0.011
MVD (CD34+) (tertiles 1, 2, 3) 1.41 (0.95-2.08) 0.087   0.667
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) 1.75 (0.90-3.43) 0.100   
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) 1.45 (1.03-2.05) 0.033   0.481